Consumers Continue Flocking to Immune-Boosting Supplements as Health Crisis Rage On

FN Media Group Presents Microsmallcap.com Market Commentary

 

New York, NY – January 25, 2021 – The health crisis has completely changed life as we know it and caused a significant shift in consumer demand for immune-boosting products, vitamins, and supplements. Now, due to growing awareness around heath, the wellness supplements market is projected to reach $386.29 billion by 2027, growing at a CAGR of 6.45%. Dietary supplement sales in the US, Canada, and the UK rose sharply during the pandemic and are expected to remain elevated, creating a lucrative opportunity for companies like Pfizer Inc. (NYSE:PFE), GlaxoSmithKline (NYSE:GSK), Archer Daniels Midland (NYSE:ADM), Abbott Laboratories (NYSE:ABT), and Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF).

 

Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF) is a leading Canadian pharmaceutical company dedicated to the commercialization of innovative prescription and over-the-counter products in Canada with a focus on Neurodegenerative Diseases, Oncology, and Hospital Specialty Products. The company joined the natural products, vitamins, and supplements space in September 2020 when it received a Natural Product License approval from Health Canada for its powerful immune system support flavonoid formulation, Hesperco.

 

A month later, Valeo Pharma announced that it had begun shipping online orders of the product, which couldn’t have come at a better time as COVID-19 cases continued to hit record highs. The product launch also comes at a time when there is a growing body of scientific evidence from researchers conducting numerous studies on the powerful antioxidant hesperidin, which is the main ingredient of Valeo Pharma’s Hesperco, and its potential role in combating viral infections.

 

Although further preclinical, epidemiological, and clinical studies are needed, in Wu et. al (2020), out of the screening of 1,066 natural substances with potential antiviral effect, plus 78 antiviral drugs already known in the literature for their binding to SARS-CoV-2 proteins, hesperidin was the only compound that could target the binding interface between viral Spike proteins and ACE-2 human receptors, which could bode well for Valeo Pharma and its newly launched Hesperco.

 

Viral Outbreaks Like COVID-19 to Become More Common

 

As countries across the globe work to vaccinate the population against COVID-19, the entire world is beginning to see light at the end of what has been a dark year. However, due to urbanization, globalization, and increasing human consumption of animal proteins, viral outbreaks will become much more common.

 

Luckily, the current health crisis has sparked a slew of research around using vitamin C and hesperidin to help boost immunity and combat the viral infection. According to research, hesperidin could be a promising candidate in the fight against COVID-19. As for vitamin C, a MDBriefcase newsletter published recently noted that vitamin C didn’t demonstrate affinity to receptors that would interfere with SARS-CoV-2 infectivity. Further, many studies on the efficacy of vitamin C in preventing respiratory diseases are inconclusive or negative. So although vitamin C sales have been soaring since the start of the pandemic as consumers look to boost their immune systems, it appears that hesperidin could be a much better suited substance to fight viral infections.

 

To capitalize on the growing demand for immune support, global healthcare leader Abbott Laboratories (NYSE:ABT) launched a new Pedialyte formulation in December that is specifically designed with key nutrients to support immune health. In addition to the electrolytes and glucose found in Abbott’s Pedialyte products, Pedialyte with Immune Support has nutrients chosen for their role in supporting the immune system, including prebiotics, vitamin B12, vitamin C, vitamin E, and zinc.

 

Agricultural giant Archer Daniels Midland (NYSE:ADM) shifted its focus towards nutrition at the perfect time, which helped the company boost its profits throughout the pandemic. The company’s nutrition division rose 35% year-over-year to $158 million in Q2 2020 due to strong sales of probiotics, fibers, and plant-based proteins.

 

“Healthy eating has significantly accelerated the purchase and consumption of alternative proteins,” said ADM CEO Juan Luciano. “A focus on nourishment and wellness is pushing microbiome solutions to the mainstream, driven by COVID-19 as people think about more health and wellness and immunity concerns.”

 

Pharmaceutical giants Pfizer Inc. (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) were already well ahead of the vitamin and dietary supplements movement. In 2012, Pfizer acquired leading vitamin supplements company Alacer, which makes Emergen-C. Then in 2019, the two companies announced that they were merging their consumer health units to create “the world’s largest consumer health company.”

 

Valeo Pharma’s Hesperco has begun shipping in Canada and will soon start in the US as well. The worldwide market for hesperidin is expected to grow at a CAGR of roughly 4.7% over the next three years to 2024.

 

For more information on Valeo Pharma, please visit this link.

 

Disclaimer:  Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

 

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Valeo Pharma, Inc.

 

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

 

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

 

Media Contact:

FN Media Group, LLC

info@financialnewsmedia.com

+1(561)325-8757

 

Source: Microsmallcap.com

Sign Up & Get FREE News Alerts From FNM Today!